SMAD3 and pulmonary fibrosis: HYDAMTIQ, a selective PARP-1 inhibitor, down-regulated the expression of TGF-β and p-Smad3, and thus exhibited an anti-fibrotic effect in bleomycin-induced lung fibrosis [34].